41490-13-5

Basic information

• Product Name: 3,5-Dichloro-4-phenylmethoxybenzoic acid
• Synonyms: 3,5-Dichloro-4-phenylmethoxybenzoic acid;4-Benzyloxy-3,5-dichloro-benzoic acid
• CAS NO: 41490-13-5
• Molecular Formula: C₁₄H₁₀Cl₂O₃
• Molecular Weight: 297.1334
• Mol File: 41490-13-5.mol

Chemical Properties

• Boiling Point: 438°Cat760mmHg
• Flash Point: 218.7°C
• Appearance: /
• Density: 1.411g/cm³
• Vapor Pressure: 1.91E-08mmHg at 25°C
• Refractive Index: 1.621
• CAS DataBase Reference: 3,5-Dichloro-4-phenylmethoxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Dichloro-4-phenylmethoxybenzoic acid(41490-13-5)
• EPA Substance Registry System: 3,5-Dichloro-4-phenylmethoxybenzoic acid(41490-13-5)

Safety Data

• Hazardous Substances Data: 41490-13-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H10Cl2O3/c15-11-6-10(14(17)18)7-12(16)13(11)19-8-9-4-2-1-3-5-9/h1-7H,8H2,(H,17,18)

Upstream product

• 99-76-3 methyl 4-hydroxylbenzoate 
• 3337-59-5 methyl 3,5-dichloro-4-hydroxybenzoate 
• 100-39-0 benzyl bromide 
• 536974-83-1 4-benzyloxy-3,5-dichlorobenzoic acid methyl ester 
• 3336-41-2 3,5-dichloro-4-hydroxybenzoic acid 
• 40689-39-2 ethyl 3,5-dichloro-4-(benzyloxy)benzoate 

Downstream Products

• 420107-66-0 (S)-2-(4-Benzyloxy-3,5-dichloro-benzoylamino)-3-hydroxy-propionic acid benzyl ester 
• 420107-67-1 (R)-2-(4-Benzyloxy-3,5-dichloro-benzoylamino)-3-iodo-propionic acid benzyl ester 
• 420107-73-9 (S)-2-(4-Benzyloxy-3,5-dichloro-benzoylamino)-3-methanesulfonyloxy-propionic acid benzyl ester 
• 420107-68-2 (2R,5R)-2-[(1S,2S)-2-Benzyloxycarbonylamino-3-(tert-butyl-diphenyl-silanyloxy)-1-trimethylsilanyloxy-propyl]-5-[(S)-2-benzyloxycarbonyl-2-(4-benzyloxy-3,5-dichloro-benzoylamino)-ethyl]-1-hydroxy-pyrrolidine-2-carboxylic acid benzyl ester 
• 354575-15-8 3,5-dichloro-4-benzoxybenzoic chloride 
• 1272528-06-9 methyl 4-(4-(benzyloxy)-3,5-dichlorobenzamido)benzoate 
• 848297-61-0 methyl 4-(3,5-dichloro-4-hydroxybenzamido)benzoate 
• 1272528-30-9 methyl 4-(4-(tert-butoxy)-3,5-dichlorobenzamido)benzoate 
• 1309825-71-5 4-(4-(tert-butoxy)-3,5-dichlorobenzamido)benzoic acid 

Relevant articles and documents

AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS

The present invention relates to compounds for stabilising the native tetrameric form of transthyretin and protecting it from proteolytic cleavage; compounds for use in the prevention and treatment of transthyretin amyloidosis; and agents and medicaments comprising such compounds. The compounds are based on a general structure A-L-B, wherein A is a group of formula (II) or of formula (III): or of formula (IV) or of formula (V) B is a group of formula (III), (IV), or (V), or a group of formula (VI) or a group of formula –R10Z, wherein: Z is selected from -CO2R', -CONR'R'', -SO2R' wherein R' and R'' are independently H or C1-C4 alkyl; and R10 is a C1-C4 alkylene or alkenylene group; and L represents a linker group which is a saturated or unsaturated chain of 5 to 13 carbon atoms.

Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer

Triple-negative breast cancer (TNBC) is an aggressive type of cancer characterized by higher metastatic and reoccurrence rates, where approximately one-third of TNBC patients suffer from the metastasis in the brain. At the same time, TNBC shows good responses to chemotherapy, a feature that fuels the search for novel compounds with therapeutic potential in this area. Recently, we have identified novel urea-based compounds with cytotoxicity against selected cell lines and with the ability to cross the blood-brain barrier in vivo. We have synthesized and analyzed a library of more than 40 compounds to elucidate the key features responsible for the observed activity. We have also identified FGFR1 as a molecular target that is affected by the presence of these compounds, confirming our data using in silico model. Overall, we envision that these compounds can be further developed for the potential treatment of metastatic breast cancer.

Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist

A ligand-based virtual screening exercise examining likely bioactive conformations of AM 580 (2) and AGN 193836 (3) was used to identify the novel, less lipophilic RARα agonist 4-(3,5-dichloro-4-ethoxybenzamido)benzoic acid 5, which has good selectivity over the RARβ and RARγ receptors. Analysis of the medicinal chemistry parameters of the 3,5-substituents of derivatives of template 5 enabled us to design a class of drug-like molecules with lower intrinsic clearance and higher oral bioavailability which led to the novel RARα agonist 4-(3-chloro-4-ethoxy-5-isopropoxybenzamido)-2-methylbenzoic acid 56 that has high RARα potency and excellent selectivity versus RARβ (2 orders of magnitude) and RARγ (4 orders of magnitude) at both the human and mouse RAR receptors with improved drug-like properties. This RARα specific agonist 56 has high oral bioavailability (>80%) in both mice and dogs with a good PK profile and was shown to be inactive in cytotoxicity and genotoxicity screens.

SYNTHETIC EPIGALLOCATECHIN GALLATE (EGCG) ANALOGS

Synthetic polyphenolic compounds of formula (I), their modes of synthesis, and pharmaceutical compositions thereof are provided herein. Use of the compounds and compositions described herein for treating cancer and for treating metabolic disorders is also provided.

Therapeutic Aryl-Amido-Aryl Compounds and Their Use

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, a

THERAPEUTIC ARYL-AM I DO-ARYL COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as "AAA compounds"), which, inter alia, a

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Production Method of Nitrogen-Containing Fused Ring Compounds

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.

PREVENTIVES/REMEDIES FOR POSTOPERATIVE STRESS

The present invention provides pharmaceutical composition for prophylaxis or/and therapy of a postoperative stress, which comprises a CRF antagonist.